Literature DB >> 24214618

Contact hypersensitivity: quantitative aspects, susceptibility and risk factors.

Peter S Friedmann1, Christopher Pickard.   

Abstract

The development of allergic sensitisation by environmental chemicals results in allergic contact dermatitis and highly undesirable morbidity and disability. This form of hypersensitivity is mediated by specific T lymphocytes that recognise the chemical sensitiser bound to self-proteins. Use of deliberate experimental contact sensitisation with dinitrochlorobenzene (DNCB) has been used to investigate the human immune system which exhibits dose-related responses. Many factors contribute to whether sensitisation occurs and the nature and magnitude of the immune response. Chemicals vary in sensitising potency, mainly reflecting their intrinsic protein-binding properties. The amount of sensitiser reaching the immune system is determined by many factors of which the concentration (dose per unit area), the relative lipid solubility and molecular weight are the most critical. Host-related factors contributing to the nature and magnitude of immune responses are mainly genetically determined including gender, age, the biochemical/physical integrity of the epidermal barrier and the quality of the innate and adaptive immune systems. The underlying mechanisms must be elucidated before it will be possible to make reliable predictions of whether a given individual will develop allergic sensitisation by a given chemical.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24214618     DOI: 10.1007/978-3-0348-0726-5_5

Source DB:  PubMed          Journal:  Exp Suppl        ISSN: 1664-431X


  4 in total

Review 1.  Etiology of epithelial barrier dysfunction in patients with type 2 inflammatory diseases.

Authors:  Robert P Schleimer; Sergejs Berdnikovs
Journal:  J Allergy Clin Immunol       Date:  2017-06       Impact factor: 10.793

2.  Skin sensitization: Uncertainties, challenges, and opportunities for improved risk assessment.

Authors:  Nicola Gilmour; Ian Kimber; Jason Williams; Gavin Maxwell
Journal:  Contact Dermatitis       Date:  2018-12-07       Impact factor: 6.600

3.  Long-Term Outcome of a Series of Patients With Narcolepsy Type 1 and Comorbidity With Immunopathological and Autoimmune Diseases.

Authors:  Francisco J Martinez-Orozco; Miguel Fernandez-Arquero; Jose L Vicario; Laura Lillo-Triguero; Elena Ameyugo; Rosa Peraita-Adrados
Journal:  J Clin Med Res       Date:  2022-08-27

4.  Comorbidity of Narcolepsy Type 1 With Autoimmune Diseases and Other Immunopathological Disorders: A Case-Control Study.

Authors:  Francisco Javier Martinez-Orozco; Jose Luis Vicario; Clara De Andres; Miguel Fernandez-Arquero; Rosa Peraita-Adrados
Journal:  J Clin Med Res       Date:  2016-05-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.